by Amy DuRoss | November 6, 2019
Today, Vineti is excited to announce a new partnership with a global contract manufacturing company serving cell therapies and gene therapies -- and not just because this represents growth for our company. We’re excited because this alignment, and…
Chain of Identity and Chain of Custody in personalized therapies -- core differences from traditional pharma
by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.
by Vineti | October 23, 2019
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former CEO and Chairman of cancer genomics trailblazer Foundation Medicine. He is a leading voice on how the life sciences will continue to…
by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.
by Tyler Wilson | October 10, 2019
Read about general approaches to UX and digital product design, and you see terms like "user delight" and "sparking delight" with increasing frequency. But sometimes, in the world of UX and product design, “delight” means getting out of the way.